| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | Synshemming
> Synshemming | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | Synshemming
> Makuladegenerasjon | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Nevrologisk
> Multippel sklerose | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | Respiratorisk
> KOLS | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | Respiratorisk
> Astma og allergi | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | Respiratorisk
> Astma og allergi | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | Hud
> Hudtilstander: de fleste typer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | Kreft
> Kreft: blod | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: de fleste typer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | Gastrointestinal
> Gastrointestinal: de fleste typer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | Kardiovaskulær
> Kardiovaskulære & hjertetilstander | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Generell helse
> Generell helse | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | Kreft
> Kreft: hud | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 5 000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Pasientadvokasi
> Helseaktivist | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Pasientadvokasi
> Helseaktivist | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | Respiratorisk
> Lungesykdommer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | Sjelden
> Sjeldne sykdommer: andre | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 1 000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Kreft
> Kreft: bryst | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Kreft
> Kreft: de fleste typer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 1 000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Hud
> Alopecia | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 5 000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Kreft
> Kreft: blod | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 5 000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | Kreft
> Kreft: blære | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | Synshemming
> Synshemming | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kreft
> Kreft: de fleste typer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 1 000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Sjelden
> Pompes sykdom | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kreft
> Kreft: kolorektal | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 10 000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generell helse
> Fedme | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | Generell helse
> Fedme | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | 100 000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | Pasientopplæring
> Pasientopplæring | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | Respiratorisk
> Lungesykdommer | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | Reumatisk
> Lupus | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Synshemming
> Synshemming | Regulatorisk partnerskap
> Delta i vurderinger av medisinsk teknologi (HTA) og refusjonsgjennomganger | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | Funksjonshemming
> Funksjonshemming: annet | Regulatorisk partnerskap
> Bidra til innsendinger for markedsføringstillatelse | 5 000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Eldre mennesker
> Eldre mennesker | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Kreft
> Kreft: bryst | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | Sjelden
> Sjeldne sykdommer: blod | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | Blod
> Sigdcelleanemi | Regulatorisk partnerskap
> Med andre helseadvokater | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Synshemming
> Makuladegenerasjon | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Eldre mennesker
> Eldre mennesker | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 10 000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | Hud
> Hudtilstander: de fleste typer | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 100 000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | Reumatisk
> Sklerodermi | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 5 000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | Sjelden
> Sjeldne lidelser: genetisk | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 1 000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Eldre mennesker
> Eldre mennesker | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100 000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Eldre mennesker
> Eldre mennesker | Påvirkning av politikk og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 10 000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Kreft
> Kreft: blod | Påvirkning av politikk og lovgivning
> Håndtering av barrierer/anomalier i medisinsk behandling | 1 000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Synshemming
> Synshemming | Påvirkning av politikk og lovgivning
> Håndtering av barrierer/anomalier i medisinsk behandling | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Kreft
> Kreft: blod | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 5 000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Pasientadvokasi
> Helseaktivist | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Nevrologisk
> Epilepsi | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 5 000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 1 000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | Kreft
> Kreft: blod | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 5 000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Sjelden
> Pompes sykdom | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Kreft
> Kreft: blod | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | 5 000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | Immun
> Primære immundefekter | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | 5 000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Eldre mennesker
> Eldre mennesker | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | 10 000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | Synshemming
> Synshemming | Prising og tilgjengelighetsadvokatur
> Delta i forhandlinger med prisrevisjonsnemnd | 100 000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | Kreft
> Kreft: blod | Prising og tilgjengelighetsadvokatur
> Krav om reduserte salgspriser fra produsenter | 10 000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immun
> Primære immundefekter | Prising og tilgjengelighetsadvokatur
> Sporing og overvåking av legemiddelpriser/legemiddelmangel | 5 000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Nevrologisk
> Epilepsi | Prising og tilgjengelighetsadvokatur
> Sporing og overvåking av legemiddelpriser/legemiddelmangel | 5 000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Sporing og overvåking av legemiddelpriser/legemiddelmangel | 1 000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | Psykisk helse
> Psykisk helse: stemningslidelser | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 10 000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immun
> Primære immundefekter | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 5 000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | Nevrologisk
> Epilepsi | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorisk
> Lungefibrose | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 100 000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | Synshemming
> Synshemming | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Sjelden
> Pompes sykdom | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | Hud
> Hudtilstander: de fleste typer | Prising og tilgjengelighetsadvokatur
> Engasjere seg i bevissthetskampanjer | 100 000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Kreft
> Kreft: blod | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 1 000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | Reumatisk
> Lupus | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 5 000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Pasientadvokasi
> Helseaktivist | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | Sjelden
> Sjeldne sykdommer: andre | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 1 000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Nevrologisk
> Epilepsi | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Kreft
> Kreft: de fleste typer | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 1 000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Kreft
> Kreft: blod | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 5 000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | Synshemming
> Synshemming | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | Kreft
> Kreft: blod | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 5 000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generell helse
> Fedme | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | Reumatisk
> Lupus | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Eldre mennesker
> Eldre mennesker | Forbedrer tilgangsveier
> Gå inn for bredere vaksinetilgang | 10 000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | Synshemming
> Synshemming | Forbedrer tilgangsveier
> Adresser ulikheter i tilgang og administrasjon | 100 000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | Kreft
> Kreft: sarkom | Forbedrer tilgangsveier
> Forbedring av tilgang til sjeldne/ultrasjelne terapier | 5 000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Pasientadvokasi
> Helseaktivist | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Hud
> Alopecia | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 5 000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Sjelden
> Pompes sykdom | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generell helse
> Fedme | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 100 000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Pasientadvokasi
> Helseaktivist | Evidensbasert pasientinnspill
> Gi Real-World Evidence (RWE) til regulatoriske myndigheter | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | Reumatisk
> Lupus | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Generell helse
> Generell helse | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | 10 000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Pasientadvokasi
> Helseaktivist | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | 1 000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | 1 000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Pasientadvokasi
> Helseaktivist | Evidensbasert pasientinnspill
> Gjennomfør undersøkelser/forskning for å generere data | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | Synshemming
> Synshemming | Evidensbasert pasientinnspill
> Gjennomfør undersøkelser/forskning for å generere data | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV og seksuell helse | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: de fleste typer | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 100 000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | Eldre mennesker
> Eldre mennesker | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 10 000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | Kreft
> Kreft: blod | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 5 000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | Kreft
> Kreft: sarkom | Institusjonell styring
> Sikre representasjon i statlige rådgivende organer | 5 000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Nevrologisk
> Epilepsi | Institusjonell styring
> Arbeide effektivt i nettverk med flere interessenter | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV og seksuell helse | Ivaretakelse av pasientrettigheter/forbedring av livskvalitet
> Beskytte/forbedre pasientopplevelsen | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | Ivaretakelse av pasientrettigheter/forbedring av livskvalitet
> Beskytte/forbedre pasientopplevelsen | 1 000 | Local | Regularly | 119045557717 |
interaksjoner
handlinger & påvirkning
36 omtaler
